Clinical Trial Update: Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-finding biomarker trial of Posiphen in early Alzheimer's and Parkinson's patients completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Parkinson Disease

Drugs mentioned

• POSIPHEN (posiphen)

Snippet

Sponsor: Annovis Bio Inc. | Conditions: Alzheimer Disease, Parkinson Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-02-28